BRPI0409424A - composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença - Google Patents

composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença

Info

Publication number
BRPI0409424A
BRPI0409424A BRPI0409424-7A BRPI0409424A BRPI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A BR PI0409424 A BRPI0409424 A BR PI0409424A
Authority
BR
Brazil
Prior art keywords
treating
patient suffering
pharmaceutical composition
parenteral administration
polypeptide
Prior art date
Application number
BRPI0409424-7A
Other languages
English (en)
Inventor
Moshe Baru
Lea Carmel-Goren
Original Assignee
Opperbas Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding Bv filed Critical Opperbas Holding Bv
Publication of BRPI0409424A publication Critical patent/BRPI0409424A/pt
Publication of BRPI0409424B1 publication Critical patent/BRPI0409424B1/pt
Publication of BRPI0409424B8 publication Critical patent/BRPI0409424B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA ADMIMSTRAçãO PARENTERAL, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE HEMOFILIA, USO DE UMA PARTìCULA COLOIDAL, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO DE UMA DOENçA". Uma composição farmacêutica para administração parenteral compreendendo uma quantidade terapeuticamente efetiva de uma proteína ou um polipeptídeo e partículas coloidais. As partículas compreendem aproximadamente 1-20 porcento em mol de um lipídeo anfipático derivado com um polímero hidrofílico biocompatível. A proteína ou o polipeptídeo é selecionada(o) do grupo consistindo de: (a) proteínas ou polipeptídeos capazes de se ligar externamente nas citadas partículas coloidais; (b) proteínas ou polipeptídeos capazes de se ligar em polímeros de famílias de poli(alquiléter), poli(ácido lático) e poli(ácido glicólico); e (c) proteínas ou polipeptídeos que incluem uma seqüência de consenso de S/T-X/I/V-I/V/Q/SS/T-X-X-X-E, na qual X pode ser qualquer aminoácido, e S, T, L, I, E, e Q possuem os significados padrão. A proteína ou o polipeptídeo não é Fator VIII (FVIII) e não está encapsulada(o) nas partículas coloidais.
BRPI0409424A 2003-04-15 2004-04-15 composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo BRPI0409424B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46270103P 2003-04-15 2003-04-15
US60/462,701 2003-04-15
PCT/IL2004/000327 WO2004091723A1 (en) 2003-04-15 2004-04-15 Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

Publications (3)

Publication Number Publication Date
BRPI0409424A true BRPI0409424A (pt) 2006-04-25
BRPI0409424B1 BRPI0409424B1 (pt) 2018-05-02
BRPI0409424B8 BRPI0409424B8 (pt) 2021-05-25

Family

ID=33299976

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409424A BRPI0409424B8 (pt) 2003-04-15 2004-04-15 composição farmacêutica para administração parenteral, e, usos de uma partícula coloidal e de partículas coloidais e uma proteína ou um polipeptídeo

Country Status (15)

Country Link
US (1) US20070167359A1 (pt)
EP (1) EP1633440B1 (pt)
JP (1) JP2006523683A (pt)
CN (1) CN1774281B (pt)
AT (1) ATE395101T1 (pt)
AU (1) AU2004229253B2 (pt)
BR (1) BRPI0409424B8 (pt)
CA (1) CA2522179C (pt)
DE (1) DE602004013769D1 (pt)
DK (1) DK1633440T3 (pt)
ES (1) ES2307009T3 (pt)
MX (1) MXPA05010926A (pt)
PL (1) PL1633440T3 (pt)
PT (1) PT1633440E (pt)
WO (1) WO2004091723A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518172D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) * 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
WO1990006952A1 (en) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH0482839A (ja) * 1990-07-20 1992-03-16 Green Cross Corp:The 蛋白質類・脂質小体複合体
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
ES2159630T3 (es) * 1994-02-08 2001-10-16 Amgen Inc Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1998032466A1 (en) * 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
ATE283034T1 (de) * 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
CA2379060A1 (en) * 1999-07-14 2001-01-25 Alza Corporation Neutral lipopolymer and liposomal compositions containing same
AU2001238469C1 (en) * 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
WO2002086117A1 (en) * 2001-04-20 2002-10-31 The University Of Vermont Compositions and methods to control bleeding
AU2002353485B2 (en) * 2001-12-04 2009-01-15 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting

Also Published As

Publication number Publication date
CN1774281B (zh) 2010-10-13
CA2522179A1 (en) 2004-10-28
BRPI0409424B8 (pt) 2021-05-25
EP1633440B1 (en) 2008-05-14
BRPI0409424B1 (pt) 2018-05-02
EP1633440A1 (en) 2006-03-15
CA2522179C (en) 2012-02-14
AU2004229253A1 (en) 2004-10-28
PL1633440T3 (pl) 2008-12-31
PT1633440E (pt) 2008-08-25
CN1774281A (zh) 2006-05-17
DE602004013769D1 (de) 2008-06-26
ES2307009T3 (es) 2008-11-16
DK1633440T3 (da) 2008-09-08
MXPA05010926A (es) 2005-11-25
US20070167359A1 (en) 2007-07-19
ATE395101T1 (de) 2008-05-15
AU2004229253B2 (en) 2009-11-05
JP2006523683A (ja) 2006-10-19
WO2004091723A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
EP0627899B1 (en) Injectable ceramic compositions and methods for their preparation and use
BR9909978A (pt) Composição farmacêutica para administração parenteral, processo para tratamento de um paciente sofrendo de hemofilia, e, uso de uma partìcula coloidal
US5204382A (en) Injectable ceramic compositions and methods for their preparation and use
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
JPH0834747A (ja) コラーゲンベースの注入可能な薬剤送達製剤およびその使用
JPH11512740A (ja) 増殖因子を含むゲル組成物
US8029769B2 (en) Protein formulation
MXPA05002991A (es) Analogos de ghrh.
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
US20050244393A1 (en) Sealant or tissue generating product
BRPI0409424A (pt) composição farmacêutica para admistração parenteral, método de tratamento de um paciente sofrendo de hemofilia, uso de uma partìcula coloidal, e, método de tratamento de um paciente sofrendo de uma doença
CA2589095C (en) Protein formulation for administering an active enamel substance
Zellin et al. Bone regeneration by a combination of osteopromotive membranes with different BMP preparations: a review
BR9202374A (pt) Composicao implantavel para a administracao parenteral de uma quantidade essencialmente uniforme e continua de uma proteina,um peptideo ou polipeptideo biologicamente ativos,processo de elevar e manter elevados niveis no sangue de uma proteina,peptideo ou polipeptideo biologicamente ativos e processo para a preparacao da composicao implantavel
NZ248446A (en) Bone growth composition containing transforming growth factor beta (tgf-beta) and demineralised bone
EP1862170B1 (en) Enamel formulation with amelogenin
US20050112087A1 (en) Pharmaceutical formulations for sustained drug delivery
US20230010110A1 (en) Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject
AU2011203284B2 (en) Protein Formulation
Zhu Stabilization and controlled release of proteins encapsulated in poly (lactide-co-glycolide) delivery systems
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED (MT)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF